Intal and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Intal (cromolyn sodium), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Spiriva, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Intal. It is created by eHealthMe based on reports of 1,614 people who have side effects when taking Intal from the FDA, and is updated regularly.

What is Intal?

Intal has active ingredients of cromolyn sodium. It is often used in asthma. eHealthMe is studying from 1,621 Intal users. Check the latest studies of Intal.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,803 drugs and 2,209 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

On Aug, 06, 2026

1,614 people reported to have side effects when taking Intal.
Among them, 12 people (0.74%) have Chronic obstructive pulmonary disease.

Could Intal cause Chronic obstructive pulmonary disease?

Among these 12 people:

How long have people been on Intal when they have Chronic obstructive pulmonary disease? *

What is the gender of people who have Chronic obstructive pulmonary disease when taking Intal? *

female: 30 %
male: 70 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Intal? *

What are other drugs people take besides Intal? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Dyspnea (difficult or laboured breathing): 5 people, 41.67%
Fatigue (feeling of tiredness): 4 people, 33.33%
Haematochezia (passage of stools containing blood): 4 people, 33.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 33.33%
Nausea And Vomiting: 4 people, 33.33%
Upper Respiratory Tract Infection: 4 people, 33.33%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 4 people, 33.33%
Hyperkalemia (damage to or disease of the kidney): 4 people, 33.33%
High Blood Pressure: 4 people, 33.33%
Gastric Cancer (stomach cancer): 4 people, 33.33%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 4 people, 33.33%
Pain: 3 people, 25.00%
Constipation: 3 people, 25.00%
Stress And Anxiety: 1 person, 8.33%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Intal and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Intal:

Intal (1,621 reports)

Browse all side effects of Intal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,803 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,209 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cromolyn sodium (the active ingredients of Intal) and Intal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.